Silk Fibroin Raw Materials Go Global | Xingyue Biotechnology and B&P KOREA Forge In-Depth Partnership to Explore New Overseas Markets

On July 2, Xingyue Biotechnology and B&P KOREA officially held a signing ceremony in South Korea, formalizing an agreement that grants B&P KOREA the exclusive marketing and distribution rights for a series of core silk fibroin raw materials across the entire South Korean territory. With the official implementation of this partnership, Xingyue Biotechnology's high-purity silk fibroin raw materials have successfully entered the South Korean market.

B&P KOREA is a highly influential raw material service provider in the South Korean industry, with over a decade of deep expertise in the bioactive raw materials sector. The company specializes in the R&D introduction, channel distribution, and market implementation of raw materials, having established a comprehensive channel system covering South Korea's pharmaceutical, biomedical, and high-end cosmetic markets. It collaborates with over 100 quality clients, and its products are widely used in skin repair, anti-aging medical aesthetics, and various medical device applications. Between 2014 and 2025, B&P KOREA served as the exclusive agent for France's HTL in South Korea, accumulating mature market promotion experience and profound industry influence.

This collaboration primarily features three self-developed core raw materials: Silk Fibroin Peptide, Soluble Silk Fibroin, and Silk Fibroin Microspheres. All three possess complete independent intellectual property rights and mature large-scale production systems. This series of raw materials offers excellent biocompatibility and stable quality. Leveraging a unique β-sheet molecular structure, they exhibit outstanding advantages including high purity, strong compatibility, stable structure, and multi-functional efficacy. They are widely suitable for diverse applications such as high-end skincare, skin repair, and regenerative medicine, demonstrating strong market competitiveness and fully meeting the strict quality requirements of the South Korean partner.

During the negotiation phase, B&P KOREA conducted multiple rounds of high-standard specialized testing and application verification on key indicators of Xingyue Biotechnology's silk fibroin series, including purity, activity, batch-to-batch stability, and application compatibility. Previously, Xingyue Biotechnology's small-molecule silk fibroin had successfully obtained the internationally recognized COSMOS certification, and its in-house production facility had also secured ISO22716 certification. Relying on a stringent production quality control system and superior biopreparation technology, the series successfully passed all evaluations and received high recognition from the B&P KOREA team, laying a solid quality foundation for long-term and in-depth cooperation between both parties.

South Korea stands at the forefront of the global medical aesthetics, skincare, and regenerative biomaterial industries, with stringent industry access standards and intense market competition, serving as a benchmark for testing the strength of biomaterial products. As a natural bioactive material, silk fibroin is increasingly favored by South Korean professional clients due to its excellent biocompatibility and significant efficacy. This powerful alliance not only represents authoritative overseas recognition of Xingyue Biotechnology's silk fibroin technology and product quality but also establishes an efficient localized market channel for the company in South Korea.

In the next phase, Xingyue Biotechnology will leverage its core technology and mass production capabilities, in conjunction with B&P KOREA's local channels, industry resources, and promotional expertise. The company will continue to uphold technological innovation and quality control, continuously refine its silk fibroin series of biomaterials, and deeply explore the high-end biomaterial market demands in South Korea. The goal is to steadily increase the penetration rate of silk fibroin raw materials in sectors such as medical dressings, regenerative repair, and anti-aging medical aesthetics in the Korean market, further enhance the brand awareness of its proprietary products in the East Asian biomaterial market, and accelerate the deep integration of its core products with the international market.